In our study, the expressions of ARRB2 in various tumors were obviously higher than that in normal tissues, ARRB2 was highly expressed in PRAD tumor tissues, and its expression was significantly different in different nodal metastasis and TP53 mutation status. This evidence concerns the gene ARRB2 and prostate adenocarcinoma.